Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2004

View Archived Issues

Nycomed terminates Oxygent license agreement

FDA approves new dosing options for Prevacid SoluTab

Chiron acquires Sagres Discovery

trans-ISA-247 completes single ascending dose study

End-of-phase II meeting held for HspE7

Icatibant awarded orphan drug status for edema in severe burn patients

U.S. phase I trial of Exherin cleared to begin

New oxymorphone ER trial protocol agreed under SPA

GOG submits IND for Xyotax study in ovarian cancer

DOV reaches agreement with FDA on clinical trial program for DOV diltiazem

Abbott and Celera form cancer therapeutics collaboration

Acusphere and Nycomed in European partnership for AI-700

MeNZB meningococcal B vaccine approved in New Zealand

Procter & Gamble license Geron's hTERT technology for research

Enrollment open in phase II Xolair peanut allergy study

Phase III study shows benefit of Bonviva/Boniva injection at extended intervals

Nebido completes European mutual recognition procedure

Histamine H3 receptor modulators claimed by Kyowa Hakko

Sponge-derived terpenoids reported by Galileo Laboratories

Tyrosine kinase inhibitors patented by Merck KGaA

ArQule describes lapachone analogues

Aminoalcohol derivatives for the treatment of urinary incontinence

AstraZeneca describes glucokinase activators

First clinical evidence of antitumor effects induced by taurolidine in glioblastoma

Potential of novel anxiolytic LY-544344

Antidepressant and anxiolytic properties of agomelatine

Anxiolytic effects of NK1 and CRF1 receptor antagonists in marmosets

Cellular process in cognition enhancement improved by 5-HT6 receptor antagonists

Antiviral nucleoside derivatives for the treatment of hepatitis C

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...